RCEL Earnings Prediction
The chart below shows how RCEL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RCEL sees a -0.87% change in stock price 10 days leading up to the earnings, and a +3.41% change 10 days following the report. On the earnings day itself, the stock moves by +0.92%. This data can give you a slight idea of what to expect for the next quarter's release.
RCEL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
19.55M
43.25%
28.63%
Gross Margin
84.56%
-0.65%
-2.92%
Operating Margin
-69.75%
4.43%
-31.41%
Net Margin
-82.91%
29.85%
-18.15%
EPS
-0.62
-82.35%
3.33%
No Data Available
RCEL Earnings Analysis
Avita Medical, Inc. Common Stock Corporation (RCEL.O) Earnings Conference Call
Positive
Record Revenue Achievement: We exceeded our second quarter record revenue, surpassing it by 29%, achieving $19.5 million in commercial revenue during Q3.
Revenue Transition Success: By the end of September, we successfully transitioned approximately 75% of our revenue base to RECELL GO, demonstrating our operational agility.
Rapid FDA Approval Execution: We managed to do this within just four months of FDA approval, showcasing our execution capabilities.
Q4 Commercial Revenue Forecast: We expect commercial revenue to be in the range of $22.3 million to $24.3 million for Q4, representing sequential growth of 14% to 25% over the third quarter.
Gross Profit Margin Outlook: Gross profit margin for the quarter was 83.7%, with expectations to be in the range of 85% to 86% for the full year 2024.
Negative
Gross Profit Margin Decline: Gross profit margin for the quarter was 83.7%, down slightly from 84.5% in the same period of 2023.
Operating Expenses Increase: Total operating expenses for the quarter were $30.2 million, compared to $21.1 million in the same period in 2023.
Operating Expenses Increase: The increase in operating expenses is primarily attributable to an increase of $4.6 million in sales and marketing expenses due to employee-related costs.
Quarterly Net Loss Increase: Net loss for the third quarter was $16.2 million, or a loss of $0.62 per basic and diluted share, compared to a net loss of $8.7 million, or a loss of $0.34 per basic and diluted share in the same period in 2023.
Cash and Marketable Securities Decline: As of September 30th, we had cash, cash equivalents, and marketable securities of $44.4 million, compared to $89.1 million as of December 31, 2023.
RCEL FAQs
How does RCEL typically perform around its earnings report dates?
Is AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RCEL Earning Call Sentiment
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
RCEL.O
0.37%Positive
The earnings call indicates financial strain with increased net loss, reduced cash position, and limited funding options. Despite revenue growth, operating expenses surged, impacting profitability. The lack of shareholder returns further dampens sentiment. The Q&A section reveals management's reluctance to provide guidance and vague responses about growth, raising concerns. While there are positives like revenue growth and manufacturing capacity, the overall financial health and lack of clear future guidance lead to a negative outlook.
